Pirfenidone Initiates a New Era in the Treatment of Idiopathic Pulmonary Fibrosis

被引：39
|
作者：
Selvaggio, Anna S. [1 ]
Noble, Paul W. [1 ]
机构：
[1] Cedars Sinai Med Ctr, Dept Med, Los Angeles, CA 90048 USA
来源：
ANNUAL REVIEW OF MEDICINE, VOL 67 | 2016年 / 67卷
关键词：
pirfenidone; idiopathic pulmonary fibrosis; interstitial lung disease; Esbriet (R); NECROSIS-FACTOR-ALPHA; OPEN-LABEL; PHASE-3; TRIAL; DOUBLE-BLIND; SURVIVAL; ACETYLCYSTEINE; PROLIFERATION; ACTIVATION; CAPACITY; RECEPTOR;
D O I：
10.1146/annurev-med-120214-013614
中图分类号：
R-3 [医学研究方法]; R3 [基础医学];
学科分类号：
1001 ;
摘要：
Idiopathic pulmonary fibrosis (IPF) is a chronic, progressive, and fatal disease that has long eluded therapy. Prognosis remains very poor, and currently lung transplantation offers the only hope of survival. Recently, great strides have been made in the development of pharmaceutical therapy to treat IPF. Pirfenidone, an oral antifibrotic agent, has been shown to slow progression of the disease and improve progression-free survival, offering new hope for patients suffering from IPF.
引用
收藏
页码：487 / 495
页数：9
相关论文
共 50 条
  • [1] Pirfenidone for the treatment of idiopathic pulmonary fibrosis
    Xaubet, Antoni
    Serrano-Mollar, Anna
    Ancochea, Julio
    EXPERT OPINION ON PHARMACOTHERAPY, 2014, 15 (02) : 275 - 281
  • [2] Pirfenidone for the treatment of idiopathic pulmonary fibrosis
    George, Peter M.
    Wells, Athol U.
    EXPERT REVIEW OF CLINICAL PHARMACOLOGY, 2017, 10 (05) : 483 - 491
  • [3] Pirfenidone and Nintedanib for Treatment of Idiopathic Pulmonary Fibrosis
    Sathiyamoorthy, Gayathri
    Sehgal, Sameep
    Ashton, Rendell W.
    SOUTHERN MEDICAL JOURNAL, 2017, 110 (06) : 393 - 398
  • [4] Pirfenidone for Idiopathic Pulmonary Fibrosis and Beyond
    Aimo, Alberto
    Spitaleri, Giosafat
    Nieri, Dario
    Tavanti, Laura Maria
    Meschi, Claudia
    Panichella, Giorgia
    Lupon, Josep
    Pistelli, Francesco
    Carrozzi, Laura
    Bayes-Genis, Antoni
    Emdin, Michele
    CARDIAC FAILURE REVIEW, 2022, 8
  • [5] Pirfenidone treatment of idiopathic pulmonary fibrosis
    Azuma, Arata
    THERAPEUTIC ADVANCES IN RESPIRATORY DISEASE, 2012, 6 (02) : 107 - 114
  • [6] Pirfenidone for the treatment of idiopathic pulmonary fibrosis
    Poletti, Venerino
    Ravaglia, Claudia
    Tomassetti, Sara
    EXPERT REVIEW OF RESPIRATORY MEDICINE, 2014, 8 (05) : 539 - 545
  • [7] Pirfenidone treatment in idiopathic pulmonary fibrosis: A Saudi experience
    Alhamad, Esam H.
    ANNALS OF THORACIC MEDICINE, 2015, 10 (01) : 38 - 43
  • [8] Pirfenidone for idiopathic pulmonary fibrosis
    Antoniu, Sabina A.
    Donner, Claudio F.
    MULTIDISCIPLINARY RESPIRATORY MEDICINE, 2009, 4 (05): : 350 - 353
  • [9] Pirfenidone in idiopathic pulmonary fibrosis
    Taniguchi, H.
    Ebina, M.
    Kondoh, Y.
    Ogura, T.
    Azuma, A.
    Suga, M.
    Taguchi, Y.
    Takahashi, H.
    Nakata, K.
    Sato, A.
    Takeuchi, M.
    Raghu, G.
    Kudoh, S.
    Nukiwa, T.
    EUROPEAN RESPIRATORY JOURNAL, 2010, 35 (04) : 821 - 829
  • [10] The effects and safety of pirfenidone in the treatment of idiopathic pulmonary fibrosis: a meta-analysis and systematic review
    Zang, Chenchen
    Zheng, Yan
    Wang, Yanqing
    Li, Lisha
    EUROPEAN JOURNAL OF MEDICAL RESEARCH, 2021, 26 (01)
12345